Why Exact Sciences Shares Rallied 16.7% in October
After reporting third-quarter financial results that were better than expected, Exact Sciences (NASDAQ: EXAS) shares gained 16.7% in October, according to S&P Global Market Intelligence.
Exact Sciences' quarterly results show that more doctors and patients are choosing its Cologuard test for colon cancer screening.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Exact Sciences Stock
€41.73
-4.920%
With 15 Buy predictions and not the single Sell prediction the community is currently very high on Exact Sciences.
With a target price of 77 € there is a hugely positive potential of 84.52% for Exact Sciences compared to the current price of 41.73 €.
